Impact of the revised WHO classification of diffuse low-grade glioma on clinical decision making: A case report

Tim A M Bouwens van der Vlis*, Ann Hoeben, Jan C Beckervordersandforth, Linda Ackermans, Daniëlle B P Eekers, Rianne M J Wennekes, Olaf E M G Schijns

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review


BACKGROUND: In the 2016 update of the World Health Organization Classification of Tumors of the central nervous system, phenotypic and genotypic parameters are integrated in diffuse low-grade glioma (LGG) tumor classification. Implementation of this combined phenotypic-genotypic characterization identifies prognostic relevant subgroups.

CASE DESCRIPTION: We report a case of a 67-year-old patient with an LGG that showed molecular characteristics similar to glioblastoma multiforme (GBM). After gross total tumor resection, the patient received combination therapy (radiotherapy and chemotherapy) according to high-grade glioma treatment protocol.

CONCLUSION: The introduction of molecular parameters to the classification of LGG will add a level of objectivity, which will yield biological homogeneous subclasses. Consequently, this will influence patient counseling and clinical decision making regarding treatment protocols.

Original languageEnglish
Article number223
JournalSurgical Neurology International
Publication statusPublished - 7 Sep 2017


  • Journal Article

Cite this